Maybe you might go away and give some thought to why the share...

Maybe you might go away and give some thought to why the share price is where it is? HINT, it's probably got little to do with clinical grade tech and more to do with:

- cash burn with high fixed costs (including massive CEO salary for microcap)
- successive down raises
- failed US IPO
- playing chicken with capital markets (ie running capital down to barely a quarter of funding)
- lengthy ASX suspension
- governances (eg Board composition, conflicts management, reneging on Feb 2023 capital raising)
- lack of independent validation (i.e. nothing but MST company sponsored research - and MST's assumptions on funding needs were highly misleading. Why didn't CDX mgmt correct this material error?)
- no revenue momentum so strategy yet to be validated
- now what appears to be a short seller
- massive overhead share supply with virtually the whole register under water. Is that you under there @mowibble?



What do you disagree with?

Just my opinion.